OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Neurology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Amyotrophic lateral sclerosis: a clinical review	438
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study	226
Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models	192
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	146
Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown	134
Two patients with acute meningoencephalitis concomitant with SARS‐CoV‐2 infection	122
Stroke care during the COVID‐19 pandemic: experience from three large European countries	118
COVID‐19‐related encephalopathy: a case series with brain FDG‐positron‐emission tomography/computed tomography findings	115
Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study	113
Cognitive decline among individuals with history of mild symptomatic SARS‐CoV‐2 infection: A longitudinal prospective study nested to a population cohort	106
A longitudinal study on α‐synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression	106
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial	104
Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus‐2 infection: A systematic review and meta‐analysis	102
Monogenic cerebral small‐vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology	101
Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity	97
Encephalitis as a neurological complication of COVID‐19: A systematic review and meta‐analysis of incidence, outcomes, and predictors	95
Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19	94
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response	92
Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature	83
Patterns of smell recovery in 751 patients affected by the COVID‐19 outbreak	82
A systematic review of neurological manifestations of SARS‐CoV‐2 infection: the devil is hidden in the details	80
Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency	80
Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis	78
The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection	78
Miller‐Fisher syndrome after SARS‐CoV‐2 infection	77

Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice	77
Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series	76
Impact of the COVID‐19 outbreak on acute stroke pathways – insights from the Alsace region in France	76
Neurological manifestations and neuro‐invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2	72
Emergency room neurology in times of COVID‐19: malignant ischaemic stroke and SARS‐CoV‐2 infection	70
Disability through COVID‐19 pandemic: neurorehabilitation cannot wait	69
Hypoperfusion intensity ratio correlates with angiographic collaterals in acute ischaemic stroke with M1 occlusion	67
European Academy of Neurology guideline on the management of medication‐overuse headache	66
COVID‐19 and herpes zoster co‐infection presenting with trigeminal neuropathy	65
Neuropathological findings from COVID‐19 patients with neurological symptoms argue against a direct brain invasion of SARS‐CoV‐2: A critical systematic review	62
European guideline and expert statements on the management of narcolepsy in adults and children	56
Guillain–Barré syndrome associated with SARS‐CoV‐2 infection. A systematic review	56
European Stroke Organisation and European Academy of Neurology joint guidelines on post‐stroke cognitive impairment	54
Increased risk of acute stroke among patients with severe COVID‐19: a multicenter study and meta‐analysis	54
COVID‐19 and ischemic stroke	53
SARS‐CoV‐2 and Guillain–Barré syndrome: AIDP variant with a favourable outcome	53
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study	53
One‐year cognitive follow‐up of COVID‐19 hospitalized patients	52
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival	50
A European Academy of Neurology guideline on medical management issues in dementia	48
Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement	48
Rapid onset of functional tic‐like behaviours in young adults during the COVID‐19 pandemic	47
Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial	47
Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel	47
Novel coronavirus and the central nervous system	47